文献速递炎症性肠病胃肠动力与功能性疾病

licensed药物对便秘型肠易激综合征腹胀疗效的系统综述与网络荟萃分析

Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-11

结果显示利那洛肽、鲁比前列酮、替纳帕诺和替加色罗均优于安慰剂,其中利那洛肽改善腹胀效果最佳(RR=0.78,95%CI 0.74-0.83,NNT=7,P-score 0.97)。间接比较未发现药物间显著差异。

要点

  • 利那洛肽、鲁比前列酮、替纳帕诺和替加色罗对IBS-C腹胀均优于安慰剂。
  • 利那洛肽在直接和网络比较中改善腹胀效果最佳,NNT=7。
  • 药物间间接比较无显著差异,需长期疗效研究。

核心结论

  • 所有FDA批准用于IBS-C的药物对腹胀均优于安慰剂。
  • 利那洛肽似乎是最有效缓解腹胀的药物。

主要发现

  • 利那洛肽290µg每日一次、鲁比前列酮8µg每日两次、替纳帕诺50mg每日两次和替加色罗6mg每日两次在成对和网络荟萃分析中均优于安慰剂。
  • 利那洛肽在成对和网络荟萃分析中腹胀改善最大(未达到腹胀改善的RR=0.78,95%CI 0.74-0.83,NNT=7,P-score 0.97)。
  • 间接比较显示各药物间无显著差异。

关键数值与推荐

  • 利那洛肽290µg每日一次:未达到腹胀改善的RR=0.78(95%CI 0.74-0.83),NNT=7,P-score 0.97。
  • 鲁比前列酮8µg每日两次、替纳帕诺50mg每日两次、替加色罗6mg每日两次均优于安慰剂。

临床怎么用

  • 对于IBS-C患者的腹胀,可考虑使用利那洛肽、鲁比前列酮、替纳帕诺或替加色罗,其中利那洛肽可能效果最佳。
  • 药物选择需结合患者具体情况,间接比较未显示药物间显著差异。

局限性

  • 需要进一步研究评估这些药物的长期疗效。
  • 需要更好地理解改善腹胀的精确机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS-C), treatment is empirical with no specific guidelines for its management. AIM: To conduct a pairwise and network meta-analysis, using a frequentist approach, of Food and Drug Administration-licensed drugs for IBS-C comparing their efficacy for abdominal bloating as a specific endpoint. METHODS: We searched the medical literature through December 2020 to identify randomised controlled trials (RCTs) in IBS-C, with abdominal bloating reported as a dichotomous assessment. Efficacy of each drug was reported as a pooled relative risk (RR) with 95% confidence intervals (CIs) to summarise effect of each comparison tested. Treatments were ranked according to their P-score. RESULTS: We identified 13 eligible RCTs, containing 10 091 patients. Linaclotide 290 µg o.d., lubiprostone 8 µg b.d., tenapanor 50 mg b.d. and tegaserod 6 mg b.d. were all superior to placebo for abdominal bloating in patients with IBS-C, in both pairwise and the network meta-analyses. Linaclotide demonstrated the greatest improvement in abdominal bloating in both pairwise and network meta-analysis (RR of failure to achieve an improvement in abdominal bloating = 0.78; 95% CI 0.74-0.83, number needed to treat = 7, P-score 0.97). Indirect comparison revealed no significant differences between individual drugs. CONCLUSIONS: We found all licensed drugs for IBS-C to be superior to placebo for abdominal bloating. Linaclotide appeared to be the most efficacious at relieving abdominal bloating. Further research is needed to assess long-term efficacy of these agents and to better understand the precise mechanism of improving bloating.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Nelson AD, Black CJ, Houghton LA, et al. Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2021. PMID: 34114657. doi:10.1111/apt.16437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。